TY - JOUR
T1 - Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients
AU - Gagliardini, Roberta
AU - Fabbiani, Massimiliano
AU - Colafigli, Manuela
AU - D'Avino, Alessandro
AU - Mondi, Annalisa
AU - Borghetti, Alberto
AU - Lamonica, Silvia
AU - Cauda, Roberto
AU - De Luca, Andrea
AU - Di Giambenedetto, Simona
PY - 2016
Y1 - 2016
N2 - Tenofovir could have a direct lipid-lowering effect. The aim of our retrospective study was to investigate changes in cardiovascular risk after switching from a tenofovir-sparing to a tenofovir-containing backbone. Lipid parameters and cardiovascular risk [calculated using 10-years Framingham Risk Score (FRS) and 5-years DAD Risk Score (DRS)] were analysed at baseline and after three months. 273 patients were enrolled. After switching, significant decreases in total cholesterol (TC) (–8.2mg/dl, p < 0.001), LDL (–8.7mg/dl, p < 0.001) and DRS (mean –0.26%, p < 0.001) were observed, while a reduction in FRS was only observed in patients with pre-switch high TC or medium-high (>10%) FRS. Pre-switch factors associated with DRS reduction were higher TC, abacavir, new generation protease inhibitors, while zidovudine predicted an increase of DRS. Our results suggest that the improvement of lipid parameters observed after switching to a tenofovir-containing backbone could lead to a significant reduction in predicted cardiovascular risk, which became more evident in subjects with higher cardiovascular risk.
AB - Tenofovir could have a direct lipid-lowering effect. The aim of our retrospective study was to investigate changes in cardiovascular risk after switching from a tenofovir-sparing to a tenofovir-containing backbone. Lipid parameters and cardiovascular risk [calculated using 10-years Framingham Risk Score (FRS) and 5-years DAD Risk Score (DRS)] were analysed at baseline and after three months. 273 patients were enrolled. After switching, significant decreases in total cholesterol (TC) (–8.2mg/dl, p < 0.001), LDL (–8.7mg/dl, p < 0.001) and DRS (mean –0.26%, p < 0.001) were observed, while a reduction in FRS was only observed in patients with pre-switch high TC or medium-high (>10%) FRS. Pre-switch factors associated with DRS reduction were higher TC, abacavir, new generation protease inhibitors, while zidovudine predicted an increase of DRS. Our results suggest that the improvement of lipid parameters observed after switching to a tenofovir-containing backbone could lead to a significant reduction in predicted cardiovascular risk, which became more evident in subjects with higher cardiovascular risk.
KW - Cardiovascular risk
KW - Cholesterol
KW - DAD risk score
KW - Dyslipidemia
KW - Framingham risk score
KW - HAART
KW - Infectious Diseases
KW - Medicine (all)
KW - Oncology
KW - Pharmacology
KW - Pharmacology (medical)
KW - Cardiovascular risk
KW - Cholesterol
KW - DAD risk score
KW - Dyslipidemia
KW - Framingham risk score
KW - HAART
KW - Infectious Diseases
KW - Medicine (all)
KW - Oncology
KW - Pharmacology
KW - Pharmacology (medical)
UR - https://publicatt.unicatt.it/handle/10807/94829
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85007036322&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007036322&origin=inward
U2 - 10.1080/1120009X.2016.1269040
DO - 10.1080/1120009X.2016.1269040
M3 - Article
SN - 1120-009X
VL - 2016
SP - 1
EP - 9
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
IS - n/a
ER -